331 related articles for article (PubMed ID: 18221231)
1. BACE inhibitors as potential therapeutics for Alzheimer's disease.
Evin G; Kenche VB
Recent Pat CNS Drug Discov; 2007 Nov; 2(3):188-99. PubMed ID: 18221231
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
3. Progress toward the discovery and development of efficacious BACE inhibitors.
Durham TB; Shepherd TA
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686
[TBL] [Abstract][Full Text] [Related]
4. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
Vassar R
Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
[TBL] [Abstract][Full Text] [Related]
5. BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity.
Evin G; Lessene G; Wilkins S
Recent Pat CNS Drug Discov; 2011 May; 6(2):91-106. PubMed ID: 21585329
[TBL] [Abstract][Full Text] [Related]
6. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
7. Investigational BACE inhibitors for the treatment of Alzheimer's disease.
Imbimbo BP; Watling M
Expert Opin Investig Drugs; 2019 Nov; 28(11):967-975. PubMed ID: 31661331
[No Abstract] [Full Text] [Related]
8. Guanidine-based β amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review.
Gehlot P; Kumar S; Kumar Vyas V; Singh Choudhary B; Sharma M; Malik R
Bioorg Med Chem; 2022 Nov; 74():117047. PubMed ID: 36265268
[TBL] [Abstract][Full Text] [Related]
9. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
10. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
Roberds SL; Anderson J; Basi G; Bienkowski MJ; Branstetter DG; Chen KS; Freedman SB; Frigon NL; Games D; Hu K; Johnson-Wood K; Kappenman KE; Kawabe TT; Kola I; Kuehn R; Lee M; Liu W; Motter R; Nichols NF; Power M; Robertson DW; Schenk D; Schoor M; Shopp GM; Shuck ME; Sinha S; Svensson KA; Tatsuno G; Tintrup H; Wijsman J; Wright S; McConlogue L
Hum Mol Genet; 2001 Jun; 10(12):1317-24. PubMed ID: 11406613
[TBL] [Abstract][Full Text] [Related]
11. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Moussa CE
Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
[TBL] [Abstract][Full Text] [Related]
12. BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status.
Evin G; Hince C
Drugs Aging; 2013 Oct; 30(10):755-64. PubMed ID: 23842796
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
14. Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage.
Netzer WJ; Bettayeb K; Sinha SC; Flajolet M; Greengard P; Bustos V
Proc Natl Acad Sci U S A; 2017 Feb; 114(6):1389-1394. PubMed ID: 28115709
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of BACE1 for therapeutic use in Alzheimer's disease.
Luo X; Yan R
Int J Clin Exp Pathol; 2010 Jul; 3(6):618-28. PubMed ID: 20661410
[TBL] [Abstract][Full Text] [Related]
16. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.
Li R; Lindholm K; Yang LB; Yue X; Citron M; Yan R; Beach T; Sue L; Sabbagh M; Cai H; Wong P; Price D; Shen Y
Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3632-7. PubMed ID: 14978286
[TBL] [Abstract][Full Text] [Related]
17. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
18. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
19. Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function.
Zhu K; Peters F; Filser S; Herms J
Biol Psychiatry; 2018 Oct; 84(7):478-487. PubMed ID: 29945719
[TBL] [Abstract][Full Text] [Related]
20. Recent Studies on Design and Development of Drugs Against Alzheimer's Disease (AD) Based on Inhibition of BACE-1 and Other AD-causative Agents.
Gupta SP; Patil VM
Curr Top Med Chem; 2020; 20(13):1195-1213. PubMed ID: 32297584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
